Neurology News and Research

Latest Neurology News and Research

Eisai calls on Alzheimer's patients and caregivers to nominate pharmacists for 2010 C.A.R.E. Pharmacy Award

Eisai Inc., in coordination with the Alzheimer's Association, calls on individuals with Alzheimer's disease and their caregivers across America to nominate local pharmacists for the 2010 C.A.R.E. Pharmacy Award. This award recognizes the vital role that pharmacists play in helping the estimated 5.3 million Americans living with Alzheimer's disease and their almost 11 million caregivers.

18 May 2010

FDA accepts for filing Sigma-Tau Pharmaceuticals' cysteamine hydrochloride ophthalmic solution NDA

Sigma-Tau Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the company's new drug application (NDA) for its cysteamine hydrochloride ophthalmic solution, an investigational therapy for the treatment of corneal cystine crystals in patients with cystinosis. The FDA also granted the NDA Priority Review status, a designation given to drugs that may provide major advances or a treatment where no adequate therapy exists.

18 May 2010

Phase II ALSTAR trial: Talampanel is safe for ALS patients

Teva Pharmaceutical Industries Ltd. today announced results from the Phase II ALSTAR trial. The trial was designed to assess efficacy, safety and tolerability of Talampanel (a selective AMPA antagonist) in reducing disease-related functional deterioration in Amyotrophic Lateral Sclerosis patients.

18 May 2010

Altered blood flow leads to falls in elderly people: Research

A new study shows that altered blood flow in the brain due to high blood pressure and other conditions may lead to falls in elderly people. The research will be published in the May 18, 2010, issue of Neurology, the medical journal of the American Academy of Neurology. Each year, unintentional falls in the United States account for more than 16,000 deaths and 1.8 million emergency room visits.

18 May 2010

Hawthorn announces licensing deal with University of Pittsburgh for novel monoclonal antibodies for cancer

Hawthorn Pharmaceuticals, Inc. today announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. The antibody portfolio targets a variety of cancers through the cell surface chondrotin sulfate proteoglycan 4 (CSPG4), which plays an important role in signaling pathways regulating tumor cell survival, growth, and motility.

17 May 2010

Athersys presents data supporting MultiStem programs

Athersys, Inc. today presented data supporting its MultiStem® programs in cardiovascular disease, neurological disease and immune system modulation, and highlighted advancements in other areas, including progress in its drug development program in the area of obesity.

15 May 2010

Children with epilepsy say their quality of life is comparable to that of healthy siblings

Children with epilepsy often face multiple challenges - not only seizures but learning, cognitive and school difficulties, side effects from medication, and, not surprisingly, social stigma from their peers.

14 May 2010

Opexa Therapeutics reports lower net loss of $1.4M for first-quarter 2010

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended March 31, 2010 and provided an update on its corporate developments.

14 May 2010

Music enhances new learning of information in AD patients

Researchers from Boston University School of Medicine (BUSM) have shown that patients with Alzheimer's disease (AD) are better able to remember new verbal information when it is provided in the context of music even when compared to healthy, older adults. The findings, which currently appear on-line in Neuropsychologia, offer possible applications in treating and caring for patients with AD.

13 May 2010

Mutations in STRAD-alpha gene can cause PMSE syndrome in Amish children: Penn researchers

So often the rare informs the common. Penn researchers investigating a regulatory protein involved in a rare genetic disease have shown that it may be related to epileptic and autistic symptoms in other more common neurological disorders.

12 May 2010

NeuroMetrix first-quarter total revenues decrease to $3.7 million

NeuroMetrix, Inc., a health care company transforming patient care through neurotechnology, today announced its financial results for the three months ended March 31, 2010.

11 May 2010

Study finds familial restless legs syndrome more prominent among French Canadian women

Restless legs syndrome, which causes an irresistible desire to move legs, appears to be a hereditary condition that's more prominent among French Canadian women and may be caused by a combination of genetic influences and environmental effects. According to a large-scale study published in the Archives of Neurology, siblings of people affected by restless legs syndrome are three and a half times more likely to develop the disease.

11 May 2010

Jazz Pharmaceuticals announces common stock public offering

Jazz Pharmaceuticals, Inc. announced today that it is offering to sell 7 million shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering.

11 May 2010

Eisai enters Canadian pharmaceutical market

Eisai Inc., a U.S. subsidiary of Eisai Co., Ltd. today announces the establishment of Eisai Limited in Canada, the world's ninth largest pharmaceutical market. As a wholly-owned subsidiary of Eisai Inc., Eisai Limited will be based in Mississauga, Ontario, one of the largest biopharmaceutical clusters and medical communities in North America.

10 May 2010

Intellipharmaceutics generic Effexor XR ANDA accepted for filing by the FDA

Intellipharmaceutics International Inc., today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of the antidepressant Effexor XR® (venlafaxine hydrochloride).

7 May 2010

ADDF awards $210,300 to Amicus Therapeutics to evaluate PCs for treating Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $210,300 to Amicus Therapeutics (Cranbury, NJ) to evaluate small-molecule, orally delivered pharmacological chaperone compounds as a novel approach for treating Alzheimer's disease.

7 May 2010

Survey reveals low awareness of postherpetic neuralgia amongst Americans

The American Pain Foundation (APF) announced today at the American Pain Society (APS) Annual Meeting the results of a national survey that showed postherpetic neuralgia (PHN), also known as after-shingles pain, continues to be a condition with low awareness amongst Americans, demonstrating a need for health care provider (HCP) intervention.

7 May 2010

Natazia tablets receive FDA approval for prevention of pregnancy

Bayer HealthCare Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for the prevention of pregnancy.

7 May 2010

Advances in genetic research could help develop personalized pain medications

In the not too distant future, it may be possible to discern an individual's genetic predisposition to chronic pain conditions and treat them proactively to prevent lifetime afflictions, according to research presented today at the American Pain Society's (www.ampainsoc.org) annual scientific meeting.

7 May 2010

54% of liver cirrhosis patients experience neurocognitive impairments

More than half of patients who have cirrhosis of the liver also display neurocognitive impairments such as short term memory loss, a study led by a Loyola University Health System researcher has found.

7 May 2010